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Abstract
Background: The Stanley Medical Research Institute online genomics database (SMRIDB) is a
comprehensive web-based system for understanding the genetic effects of human brain disease (i.e.
bipolar, schizophrenia, and depression). This database contains fully annotated clinical metadata and
gene expression patterns generated within 12 controlled studies across 6 different microarray
platforms.
Description: A thorough collection of gene expression summaries are provided, inclusive of
patient demographics, disease subclasses, regulated biological pathways, and functional
classifications.
Conclusion: The combination of database content, structure, and query speed offers researchers
an efficient tool for data mining of brain disease complete with information such as: cross-platform
comparisons, biomarkers elucidation for target discovery, and lifestyle/demographic associations to
brain diseases.
Background
Brain disease studies based on experiments using genome-
wide measurements with microarrays are traditionally
challenging as compared to other disease areas. The bio-
logical results are often hindered by statistical issues of
small sample sizes, small effect sizes, and patient-to-
patient variability [1-3]. Also, clinical information for
patients is typically sparse, such that unknown clinical
covariates can either confound or confuse many of the
gene expression patterns and trends, as opposed to the
primary disease. Corrections using such clinical informa-
tion can greatly improve inference in determining markers
for disease, as well as elucidating patterns within the dis-
ease.
Technical problems in microarray data can also affect the
analyses. Meaningful results are often limited by array
platform-to-platform comparisons and overall organiza-
tion/presentation of large data sets/results. Studies con-
ducted on disparate platforms are inherently more
difficult to analyze than those conducted on the same
platform [4]. Cross-platform comparisons present analy-
sis challenges due to differences in scaling and sensitivity
(to name a few) which introduce inconsistencies in repro-
ducibility [5-8]. Large data sets and comprehensive results
summaries present another challenge that requires good
organization of both analytical and bioinformatics infor-
mation (e.g. expression profiles, gene summary informa-
tion, pathway diagrams, fold change value comparisons,
etc.) into a user-friendly format to facilitate efficient data
mining. A relational web-based tool that logically com-
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bines all of these factors can enhance researchers' ability
to determine the underlying genomic patterns in brain
disease.
The SMRIDB is an online data warehouse and analytical
system designed to aid researchers in understanding the
biological associations both between and within the brain
disorders of schizophrenia, bipolar, and major depres-
sion. This open source database combines genomic pat-
terns of brain disease with patient clinical metadata into a
user-friendly query interface to enable efficient data min-
ing for purposes of biomarker discovery and elucidating
biological mechanisms of brain disease. The metadata
includes a full summary of clinical history for each patient
with hyperlinks to disease-level information, such that
demographic- and lifestyle-associated effects can be deter-
mined as they relate to brain disorders. The genomic data
has been compiled from 12 separate labs (identified as
studies), each data set generated from brain tissue isolated
from two controlled populations of 165 patients, diag-
nosed with one of the three brain disorders (plus unaf-
fected control brain tissue). This genomic data has been
generated across 6 separate human array platforms
(Affymetrix: hgu133a, hgu133plus, hgu95av2, Agilent,
Codelink, and cDNA custom array) providing patterns/
trends and analytical inferences that are not limited by
platform dependencies.
Construction and content
Bioinformatics mappings
NCBI's Database for Annotation, Visualization and Inte-
grated Discovery (DAVID 2.0) was used as the standard
source for gene annotation information [9]. The primary
fields extracted from DAVID include: LocusLink, gene
symbol, and gene summary. Additional annotations
include gene product mappings to the Kyoto Encyclope-
dia of Genes and Genomes (KEGG), and Gene Ontology
Consortium (GO) for pathway and GO terms/classes,
respectively. For Affymetrix arrays, queries were based on
the Affymetrix probe ID (AFFYID). For other arrays, the
Genbank accessions (GENBANK) were used.
Individual study-level analysis
For each of the individual studies, a series of analyses were
performed. Each array (representing a single patient) was
subjected to a quality control (QC) analysis for chip-level
parameters (e.g. scaling factor, gene calls, control gene
ratios, average correlation) with respect to the reference
distribution for those parameters across the arrays. This
QC analysis is represented with both graphical representa-
tions (e.g. heatmaps, scatter plots, and histograms (Figure
1)) and table summaries, allowing users to readily iden-
tify those arrays determined to be outliers in the study. A
total of 41 clinical demographic variables (Tables 1, 2, 3,
4) were assessed for their effects on a gene-by-gene basis.
Continuous variables and ordered categorical variables
were cut at values as close as possible to the median (e.g.
PMI>30 vs. PMI<30; Drug Use = 'Heavy' vs. Drug Use =
'None, Light, Moderate'). The genes determined to be
most significant (p-value<0.01 and fold change >1.3) for
Table 2: Patient demographic variables for Bipolar patients
Bipolar Patient Variables Values
Bipolar Severity Severe/Other
Bipolar Heavy Alcohol Use Yes/No
Bipolar Heavy Drug Use Yes/No
Bipolar Psychotic Feature Yes/No
Bipolar Sudden Death Yes/No
Bipolar Suicide Status Yes/No
Bipolar Lifetime Antipsychotics >0 Yes/No
Bipolar Antipsychotics Yes/No
Bipolar Antidepressants Yes/No
Bipolar Mood Stabilizer Yes/No
Bipolar Lithium Yes/No
Bipolar Valproate Yes/No
Table 1: Patient demographic variables for all diseases
All Patient Variables Values
Age >45 Yes/No
PMI > 30 Yes/No
Brain pH > 6.5 Yes/No
Left Brain Yes/No
Sex Male/Female
Smoking at Time of Death Yes/No
Herpes simplex virus 1 OD High/Low
Herpes simplex virus 2 OD High/Low
Toxolgg OD High/Low
EBV OD High/Low
HHV6 OD High/Low
CMV OD High/Low
Hervk 18 SNP Positive/Negative
Hervk 18 Expression Positive/Negative
Table 3: Patient demographic variables for Schizophrenic 
patients
Schizophrenic Patient Variables Values
Schizophrenia Severity Severe/Other
Schizophrenia Heavy Alcohol Use Yes/No
Schizophrenia Heavy Drug Use Yes/No
Schizophrenia Paranoid/Undiff
Schizophrenia Sudden Death Yes/No
Schizophrenia Suicide Yes/No
Schizophrenia Lifetime Antipsychotics >45,000 Yes/No
Schizophrenia Antichollnergic Yes/No
Schizophrenia Antidepressants Yes/No
Schizophrenia Stabilizer Yes/No
Schizophrenia Lithium Yes/No
Schizophrenia Valproate Yes/NoBMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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each demographic variable is reported in a table, accom-
panied by a summary of the percentage of significant
genes for each variable (Figure 2). Each gene found to be
significant for a demographic variable links to a gene-cen-
tric page (discussed in Gene details page section). Such
results allow researchers to determine markers that are
related to lifestyle or clinical demographical information
and identify confounding variables within a disease class.
The three disease classes were analyzed to provide a list of
discriminating genes (adjusted for the demographic terms
that met the criteria of significance for that gene) or mark-
ers indicative of disease (Figure 3) between the control
patients and each disease class (schizophrenia, bipolar,
depression). In addition to table summaries (genes in
table also link to their respective gene detail page), both
Table 4: Patient demographic variables for Depressed patients
Depressed Patient Variables Values
Depression Heavy Alcohol Use Yes/No
Depression Heavy Drug Use Yes/No
Depression Suicide Yes/No
QC histograms Figure 1
QC histograms. Examples of distribution thresholds used to assess outliers for an individual study.BMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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Demographic gene table Figure 2
Demographic gene table. Table of genes determined to be significant (p < 0.01 and fold change > 1.3) with the demographic 
variables for an individual study.
Demographic Analysis for Study ID 1 
Gene Name Probe ID Fold P-Value Demographic
WD repeat domain 12 218512_at -1.300079 0.002726145 Schiz. Rate of Death
ribosomal protein L32 200674_s_at -1.300112 0.002549543 Schiz. Rate of Death
src family associated phosphoprotein 2 204361_s_at -1.300366 0.0026311 Hsv2 OD z-score
collagen, type I, alpha 2 202403_s_at -1.300609 0.001424433 Schiz. Antidepressants 
1
KIAA0406 gene product 212898_at -1.301134 8.636145E-4 BP Rate of Death
manic fringe homolog (Drosophila) 204153_s_at -1.301626 0.009516091 Schiz. Antidepressants 
1
intercellular adhesion molecule 5, telencephalin 206906_at -1.301903 0.008547785 Schiz. Anticholinergic
glyceraldehyde-3-phosphate dehydrogenase 212581_x_at -1.301906 4.491425E-4 BP Rate of Death
GPI deacylase 220576_at -1.303601 0.006497378 Hsv2 OD z-score
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 14.5kDa 206936_x_at -1.304087 0.001846594 Schiz. Suicide Status
CGI-105 protein 218504_at -1.304355 0.002839769 Schiz. Rate of Death
GCN5 general control of amino-acid synthesis 5-like 1 (yeast) 202592_at -1.30492 0.003567047 BP Lifetime 
Antipsychotics
platelet-derived growth factor receptor, alpha polypeptide 203131_at -1.305651 5.900375E-4 Schiz. Rate of Death
6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear 
factor 1 alpha (TCF1) 203557_s_at -1.306751 0.003184587 Schiz. Rate of Death
erythrocyte membrane protein band 4.1-like 3 212681_at -1.306797 0.00754858 Schiz. Mood Stabilizer 
1/2 Valproate
phosphatidylinositol glycan, class K 209707_at -1.307563 0.003827987 Schiz. Rate of Death
RAB11B, member RAS oncogene family 217793_at -1.309066 0.006303166 Schiz. Antidepressants 
1
ribosomal protein L22 208768_x_at -1.309477 0.003056197 Schiz. Rate of DeathBMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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Disease gene table Figure 3
Disease gene table. Table of genes determined to be significant (p < 0.01 and fold change > 1.3) with the disease for an indi-
vidual study.
Disease Analysis for Study ID 1 
Gene Name Probe ID Fold P-Value disease
metallothionein 1X 204326_x_at 1.490134 0.008826667 Unaffected
control/Schizo.
metallothionein 2A 212185_x_at 1.415044 0.008509821 Unaffected
control/Schizo.
solute carrier family 14 (urea transporter), member 1 (Kidd blood group) 205856_at 1.405315 0.001412296 Unaffected
control/Schizo.
metallothionein 1E (functional) 212859_x_at 1.394182 0.007688833 Unaffected
control/Schizo.
heat shock 90kDa protein 1, alpha 211969_at -
2.197723 3.636968E-4 Unaffected control/BP
poly(rC) binding protein 2 204031_s_at -
1.891557 1.620039E-4 Unaffected control/BP
calcium/calmodulin-dependent protein kinase kinase 2, beta 213812_s_at -
1.823965 4.937033E-4 Unaffected control/BP
spinocerebellar ataxia 1 (olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1) 203231_s_at -
1.819936 0.001053595 Unaffected control/BP
myelin basic protein 210136_at -
1.789055 0.002000251 Unaffected control/BP
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon
polypeptide 210317_s_at -
1.787488 1.089464E-4 Unaffected control/BP
tumor differentially expressed 1 211769_x_at -
1.783736 8.196207E-4 Unaffected control/BP
likely ortholog of mouse immediate early response, erythropoietin 4 201593_s_at -
1.756236 4.611386E-4 Unaffected control/BP
WD repeat and SOCS box-containing 1 210561_s_at -
1.743396 2.464709E-4 Unaffected control/BP
tumor differentially expressed 1 221473_x_at -
1.720738 0.001397721 Unaffected control/BPBMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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2D clustering heatmaps (Figure 4) and principal compo-
nents scatter plots (Figure 5) are provided for a visual rep-
resentation of the data. Utilizing these disease markers,
the most regulated pathways and GO terms were identi-
fied for each disease comparison based on a Fisher's exact
test. Each pathway and GO term (from each of the three
GO functional classifications separately) is ranked by p-
value for each disease comparison to indicate the most
regulated pathway/GO terms (Figure 6). Additionally,
each pathway and GO term in the table links to a path-
way/GO detail page.
Pathway/GO details page
Within this pathway/GO detail page is a comprehensive
summary of the gene expression profiles for each gene
that is mapped to the associated pathway or GO term
within each separate disease class. A confidence interval
boxplot is provided within each disease comparison
inclusive of every gene mapped to that pathway or GO
term queried in the study (Figure 7), along with a link to
the pathway network representation provided by KEGG.
Such results allow researchers to understand the most reg-
ulated biological mechanisms and cellular sites for each
disease class.
Gene details page
For every probe across the 6 array platforms, primary
annotations were determined such that each probe is
mapped to either a gene name or EST identifier (refer to
Bioinformatics mappings section for mapping criteria).
So each gene summary page contains probe-level infor-
mation for all of the 6 array platforms and 12 studies
within the database. In addition to general bioinformatics
annotations (e.g. biological summary, LocusLink ID,
PubMed search link, and gene symbol) and pathway/GO
mappings (associations with gene that link to pathway/
GO-centric pages), this page contains gene expression
summaries for every probe that maps to this gene across
all studies (Figure 8). A cross study 'consensus' fold
change was calculated for each gene and disease/demo-
graphic comparison, based on a weighted combination of
the individual fold changes and standard errors for the
probes that map to each gene across the platforms/stud-
ies. Weights were determined in a probeset-specific man-
ner to account for the differing levels of precision
associated with each probeset that maps to a given gene
across the platforms. Confidence interval boxplots inclu-
sive of each probe for the gene on this page are provided
for the following: normalized expression across all
patients, fold changes within each disease class, percent
present calls for the former two comparisons, and all 41
demographic variables for the gene (Figure 9). Addition-
ally, there is a general search engine that supports queries
of gene name, symbol, pathway, GO term, and LocusLink
ID designed for direct access to any gene detail page or
pathway/GO detail page.
Cross-platform analysis
To date, making comparisons across disparate gene
expression platforms has been very difficult [5-8]. Chip 
manufacturing differences such as probe selection,
processing protocols, and spot normalization algorithms
contribute to variability that can distort mRNA transcript
abundance measurements and introduce inconsistencies
to hinder cross-platform comparisons. Some success has
been demonstrated in reducing the problem to the most
consistent sequence-verified gene annotations between
two platforms (e.g. UniGene cluster membership) and
examining correlations, ratio values, or gene calls,
although sensitivity and global statistical inference of
such approaches still remains a challenge [7,10-12].
The cross-platform comparisons within the SMRIDB are
based on scaled representations of individual study-level
analysis across studies to extract biological patterns and
relationships. These cross-platform results are provided
for both the gene level (Figure 10) and pathway/GO level
in a study-centric (Figure 11) and gene-centric (Figure 12)
visualization. For the gene-level cross-platform analysis,
the fold changes and confidence intervals are calculated as
described in the Gene details page section. For the path-
way/GO-level analysis, the p-values calculated by the
Fishers's exact test from each study individually for dis-
ease-related genes were scaled across studies and provided
in an interactive sortable heatmap, where each cell has a
clickable link to a pathway/GO details page. Additionally,
this same analysis and visual representation is provided
for the demographic variables (Figure 13). Such a data
representation allows researchers to quickly determine the
most regulated pathways or functional classifications
across all platforms or for a specific demographic variable.
Utility and discussion
The user interface was constructed to enable intuitive nav-
igating and efficient data mining. The main site contains
the primary index for the database's 4 general segmented
areas: Patients, Studies, Genes, and Analysis, each of
which is a gateway to unique focus areas, with mutual
associations between each, such as clinical information
vs. genomics results and individual study content vs.
cross-platform combined analyses. The Genes tab con-
tains an open text search engine (with partial matches) to
enable queries by gene, LocusLink, or pathway for any sin-
gle or combined study results.
The intended users of the database include any genomics
researchers facing the persistent challenges of sensitivity
for biomarker discovery and cross-platform microarrayBMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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Study-level visuals (heatmap) Figure 4
Study-level visuals (heatmap). Two-dimensional hierarchical clustering heatmap containing the most significant genes in 
schizophrenic disease for an individual study.BMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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Study-level visuals (PCA scatter plot) Figure 5
Study-level visuals (PCA scatter plot). Principal components plots generated with the most significant genes in schizo-
phrenic disease for an individual study.
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Pathway table Figure 6
Pathway table. Table of most regulated pathways for an individual study.
Pathway Analysis for Study ID 1 
Pathway Absolute RR Z-Score P-Value Disease
Ubiquinonebiosynthesis 110.269 0.0 Unaffected control/BP
Alzheimer's disease 7.309 0.0 Unaffected control/BP
D-Arginine andD-ornithine metabolism 5.33 0.0 Unaffected control/BP
Alzheimer's disease 4.487 7.0E-6 Unaffected control/Schizo.
Dentatorubropallidoluysian atrophy (DRPLA) 4.357 1.3E-5 Unaffected control/BP
Phosphatidylinositol signaling system 4.293 1.8E-5 Unaffected control/BP
Parkinson's disease 3.808 1.4E-4 Unaffected control/BP
RNA polymerase 2.658 0.007861 Unaffected control/BPBMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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Fold change boxplots Figure 7
Fold change boxplots. Fold change (with confidence intervals) values for bipolar patients for every gene that maps to the 
Alzheimer's pathway.
Fold Change (Bipolar)BMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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Gene summary page (truncated) Figure 8
Gene summary page (truncated). Portion of gene summary page for the gene reelin (RELN).
Gene Detail for Gene ID 3858
information about the gene detail pages
Probes
Gene
Symbol RELN
Gene
Name reelin
Summary
[SUMMARY:] This gene encodes a large secreted extracellular matrix protein thought to control cell-cell interactions critical for cell positioning and 
neuronal migration during brain development. This protein may be involved in schizophrenia, autism, bipolar disorder, major depression and in migration 
defects associated with temporal lobe epilepsy. Mutations of this gene are associated with autosomal recessive lissencephaly with cerebellar hypoplasia. 
Two transcript variants encoding distinct isoforms have been identified for this gene. Other transcript variants have been described but their full length 
nature has not been determined.
Locuslink
Id 5649
Pub Med 
Search Search on Locuslink Id =5649
Array Probe Id
hgu95a 37530_s_at
hgu95av2 37530_s_at
hgu133a 205923_at
hgu133plus 205923_at
codelink NM_005045.1_PROBE1
agilent 857060
agilent 2568422
cDNA 40791BMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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Fold change boxplots Figure 9
Fold change boxplots. Fold change (with 99% confidence intervals) for the gene reelin across all 41 demographic variables.BMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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Summary statistic table Figure 10
Summary statistic table. Gene-level summary table of significant probes across all studies for depression.
Cross Study Analysis of Disease (Genes)
Significant probes for Depression (up-regulation)
Select Disease: Depression
Select Analysis Table(s): Significant probes
submit
Depression Up Regulation
Total Percent of Probes with p<.05
Probes 0-5% 6-10% 11-15% 16-20% 21-25% 26-30% 31-35% 36-40% 41-45% 46-50% 50-100%
1-3 4050 0 0 0 0 0 67 0 0 188 317
4-5 3020 0 0 534 230 0 0 47 0 16 6
6-10 2607 102 648 499 84 72 98 14 16 13 0
11-15 357 239 23 93 21 13 5 1 1 0 0
16-20 46 44 17 10 3 1 0 0 0 0 0
21-25 13 6 5 3 1 2 0 0 0 0 0
26-30 5 4 1 1 0 1 0 0 0 0 0
31-40 2 2 0 2 0 0 1 0 0 0 0
41-50 0 0 0 0 0 1 0 0 0 0 0
>50 0 0 0 0 0 0 0 0 0 0 0
Patients Studies Genes Analysis About DatabaseBMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
Page 14 of 17
(page number not for citation purposes)
Pathway clickable heatmap Figure 11
Pathway clickable heatmap. Study-centric clickable heatmap of top regulated pathways in schizophrenia. Each column can 
be sorted by a particular study or the three last summary columns. Study 12 was omitted from this visual.BMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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GO term clickable heatmap Figure 12
GO term clickable heatmap. Gene-centric clickable heatmap of top regulated GO terms (molecular function) in schizo-
phrenia. Each column can be sorted by a disease.BMC Genomics 2006, 7:70 http://www.biomedcentral.com/1471-2164/7/70
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Pathway/demographic clickable heatmap Figure 13
Pathway/demographic clickable heatmap. Demographic variable clickable heatmap of top regulated pathways. Each col-
umn can be sorted by a demographic variable.Publish with BioMed Central    and   every 
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comparisons. However, the content within the SMRIDB is
primarily designed for biologists, clinical researchers, bio-
informaticians, and scientist in the field of brain disease.
The size and scope of the SMRIDB makes it a unique con-
tribution to genomics-based brain disease research. With
combined gene expression profile summaries across 12
studies and 6 platforms, there is greater confidence in sci-
entific findings such as biomarkers for disease, biological
functional roles, and regulated pathways, as compared to
results obtained from any one individual study.
Conclusion
The SMRIDB is a comprehensive data mining tool to ena-
ble researchers to elucidate the biological mechanisms of
bipolar disorder, schizophrenia, and depression. A diverse
patient population combine with data generated across
six microarray platforms and 12 studies to provide robust
results to enhance the understanding of brain disease.
Availability and requirements
The SMRIDB can be accessed at https://www.stanleygen
omics.org. All users must register (name and email
address) to obtain a username and password.
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